Edison issues ADR update on Hutchison China MediTech (HCM)

LONDON, UK / ACCESSWIRE / October 10, 2019 / Hutchison China MediTech (NASDAQ:HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumors (NET). The data support a China NDA submission (imminent), with surufatinib likely to be the first of HCM's non-partnered assets to reach the market (late 2020). NET tumors are highly prevalent, fragmented in primary origin and are an unmet medical need. Surufatinib could be the first universal drug to treat NET in all patients regardless of tumor subtype; the SANET-p Phase III data in (pancreatic NET H120), is critical to widening its market potential. The global (US and Europe) registration Phase III study is planned for H120. CK Hutchison Holdings (CKHH) reduced its holding by 1.3% to below 50% (49.9%). We see this as a significant positive as it removes the significant overhang on the shares. We value HCM at $5.7bn.

We value HCM at $5.7bn ($42.78/ADS) vs $5.7bn ($42.62/ADS) previously. We now forecast surufatinib launch in China in late 2020 (previously early 2021) based on an October 2019 China NDA submission. We have increased 2020 R&D expenses and rolled forward our model in time.

Click here to view the full report.

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:
Dr Susie Jana, +44 (0)20 3077 5700
Dr Daniel Wilkinson, +44 (0)20 3077 5734
[email protected]
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv

SOURCE: Hutchison China MediTech